Healthcare Marijuana, Inc. investment AXIM® Biotechnologies appears to expand impressive intellectual house portfolio with patent on cannabinoid chewing gum for migraines.
Top cannabinoid analysis and new drug improvement enterprise AXIM® Biotechnologies not too long ago filed a provisional patent application with the United States Patent and Trademark Workplace (USPTO).
The provisional patent application is for a patent on a chewing gum composition comprising of cannabinoids and parthenolide (feverfew extract) for remedy of symptoms of migraines. This provisional application establishes AXIM®’s filing date for the patent and offers AXIM® a single year to file a formal patent application for their invention.
AXIM® Biotechnologies has currently constructed a powerful intellectual house portfolio with five issued patents, 12 pending patents, and 28 trademarks. The enterprise is hunting to expand on this IP portfolio with further new drugs and customer goods formulated with cannabinoids, which includes this cannabinoid-primarily based remedy for migraine symptoms.
The enterprise is at present in improvement or trials for cannabinoid chewing gum remedies for symptoms connected to various sclerosis, chemotherapy, AIDS, drug-connected psychosis, and restless leg syndrome, with extra on the way.
“AXIM is most effective recognized for its patent on chewing gum containing cannabinoids and our flagship CBD chewing gum solution, CanChew+,” mentioned AXIM CEO John W. Huemoeller II.“With this patent application and AXIM’s present cannabis chewing gum goods at present in improvement, we program to bring a assortment of remedy possibilities to the market place.”
With this new provisional patent application, AXIM® plans to create a cannabinoid chewing gum that includes cannabidiol ( CBD) and/or cannabigerol (CBG), as nicely as feverfew extract, for the remedy of symptoms that generally accompany migraines, such as headache, discomfort, nausea, and light sensitivity.
Feverfew has been established to relieve and avert symptoms of migraines. The enterprise is hunting to combine these effects with the rewards of cannabinoids like CBD and CBG for a novel way for migraine sufferers to come across fast relief.
The new formulation will be delivered by way of AXIM®’s proprietary sustained-release chewing gum delivery technologies to release active components in a controlled manner into the oral cavity for a speedy but lasting onset of effects.
There is at present no permanent remedy for migraines, so remedies are aimed at relief of symptoms. The market place for migraine remedies has been developing as international incidence has improved. According to Grand View Investigation, Inc., the international migraine remedy market place size is anticipated to attain $7.eight billion by 2025. Though the migraine market place is hugely competitive, numerous migraine sufferers are hunting for option remedies like CBD that do not function that harsh synthetic chemical substances located in most present remedy possibilities.
“As a enterprise of firsts, Healthcare Marijuana, Inc. is proud to help AXIM as it files this patent application for the 1st-ever cannabis-primarily based gum formulated to treat the symptoms of migraines,” mentioned Healthcare Marijuana, Inc. CEO Dr. Stuart Titus. “Studies have estimated that migraines have an effect on roughly 38 million folks in the U.S. and the market place at present lacks an efficient organic remedy solution for these folks.”
You can find out extra about AXIM® Biotechnologies, which includes its most recent new drug developments, right here, or take a look at our news feed for the most recent from across our portfolio of firms.